Skip to main content
 
 


AGC Pharma Chemicals

Who we are

Based on more the 40 years of experience in contract development and manufacturning of intermediates and APIs, AGC continues robust supply of the product with quality control in compleance with cGMP.
AGC has extensive experience in general chemical reactions, halogenation reactions including fluorination, cryogenic reactions.

Our vision:

Your first choice for a reliable and trusted partner.

Our mission:

In the life sciences field, we provide high-quality services and products based on advanced expertise, enriching society as a whole.

Proven Track Record: Trust and Reliability

Extensive Equipment Capabilities

Advanced Development Capabilities

Values

AGC Pharma

Customer Orientation

We deeply understand your challenges and objectives and provide you with the best solutions.

AGC Pharma

Challenge

We always “Look Beyond” and tirelessly pursue innovations in technology, products, and services.

AGC Pharma

Operational Excellence

We seek diverse capabilities and personalities of individuals of all backgrounds and beliefs, and by leveraging each other’s strengths we create value as One Team.

AGC Pharma

Team Excellence

We seek diverse capabilities and personalities of individuals of all backgrounds and beliefs, and by leveraging each other’s strengths we create value as One Team.

AGC Pharma

Sautainability

We contribute to creating a sustainable society and constantly grow and evolve.

AGC Pharma

Trust

We create trust with all stakeholders, internally and externally, by acting with integrity.

Our History

1907
AGC founded in Japan

• AGC founded in Japan

1985
Contract Manufacturing/Supply of Fluorinated Intermediates for Antibacterial Agents to Pharmaceutical Companies

• Contract Manufacturing/Supply of Fluorinated Intermediates for Antibacterial Agents to Pharmaceutical Companies

1997
Establishment of Wakasa AGC Fine Chemical (currently AGC Wakasa Chemical)

• Establishment of Wakasa AGC Fine Chemical (currently AGC Wakasa Chemical)

2003
Completion of Full-Scale GMP-Compliant Multipurpose Clinical Trial Drug Manufacturing Facility at Chiba Plant

• Completion of Full-Scale GMP-Compliant Multipurpose Clinical Trial Drug Manufacturing Facility at Chiba Plant

2008
Approval for Manufacturing and Marketing of the Glaucoma Treatment API “Tafluprost”

• Approval for Manufacturing and Marketing of the Glaucoma Treatment API “Tafluprost”

2013
AGC Wakasa Chemical Establishes Kamiji Plant in Wakasa Techno Valley

• AGC Wakasa Chemical Establishes Kamiji Plant in Wakasa Techno Valley

2019
Acquisition of a Synthetic Pharmaceutical API Manufacturing Facility in Spain (Currently AGC Pharma Chemicals Europe)

• Acquisition of a Synthetic Pharmaceutical API Manufacturing Facility in Spain (Currently AGC Pharma Chemicals Europe)
• Increased Production Capacity at Chiba Plant Tenfold

2020
Decision to Expand Facilities at AGC Pharma Chemicals Europe

• Decision to Expand Facilities at AGC Pharma Chemicals Europe

2021
Decision to Expand Facilities at AGC Wakasa Chemical’s Kamiji Plant

• Decision to Expand Facilities at AGC Wakasa Chemical’s Kamiji Plant

2022
Decision to Expand Facilities of AGC Pharma Chemicals Europe

• Decision to Expand Facilities of AGC Pharma Chemicals Europe

Our Locations

Explore our Europe and Japan sites to understand how our advanced facilities, labs, and integrated services support your projects. Discover more about our technologies through virtual site tours. For detailed support, contact our team.

Our Executive Leadership Team